NCT03298022View on ClinicalTrials.gov

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

April 6, 2020

Study Completion Date

June 1, 2020

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

ALTB-168

monoclonal antibody

Trial Locations (12)

10021

Weill Cornell Medical College, New York

14642

University of Rochester Medical Center, Rochester

20850

Capitol Research, Rockville

33853

Wellness Clinical Research (WCR), Lake Wales

60611

Northwestern University Feinberg School of Medicine, Chicago

60637

University of Chicago, Chicago

72205

Lynn Institute of the Ozarks, Little Rock

77030

Baylor College of Medicine, Houston

92660

Stomach Doctor - Surinder Saini, MD - Fountain Valley, Newport Beach

98195

University of Washington Medical Center (UWMC) - Digestive Disease Center, Seattle

33016-2202

Wellness Clinical Research (WCR), Hialeah

00694

Wellness Clinical Research (WCR), Vega Baja

Sponsors

Lead Sponsor

AltruBio Inc.
All Listed Sponsors
lead

AltruBio Inc.

INDUSTRY